Over the years, TCT® has cemented its reputation as the foremost venue for unveiling data that profoundly influence patient care and therapeutic guidelines in cardiovascular medicine. The symposium’s late-breaking clinical trials sessions remain among the most eagerly anticipated components, offering the first presentation of novel device technologies, pharmaceutical agents, and interventional techniques designed to improve outcomes in heart and vascular disease. In 2025, the program includes 28 such trials that underscore recent innovations targeting minimally invasive procedures, drug delivery systems, and diagnostic technologies.

Among the highlights slated for Sunday, October 26, are the one-year results of the SELUTION DeNovo trial. This randomized study compares percutaneous coronary intervention (PCI) using a sirolimus-eluting balloon combined with provisional stenting against the conventional approach of systematic drug-eluting stent (DES) implantation for de novo coronary lesions. The nuanced understanding of vascular healing and restenosis suppression offered by sirolimus drug delivery could redefine interventional strategies in complex coronary disease.

Another significant focus on this day is the randomized comparison between intravascular lithotripsy and cutting balloon angioplasty for calcified coronary artery disease, as demonstrated in the Short-CUT and VICTORY trials. These studies evaluate the mechanobiological impact and procedural efficacy of lithotripsy—a novel modality employing sonic pressure waves to fracture calcific plaques—contrasted with conventional mechanical plaque modification techniques. The findings could optimize lesion preparation protocols and improve stent expansion in heavily calcified vessels, a notorious challenge in interventional cardiology.

The day’s scientific agenda further includes analyses from the STORM-PE trial on mechanical thrombectomy combined with anticoagulation versus anticoagulation alone in acute intermediate-high risk pulmonary embolism. This multicenter investigation assesses whether adjunctive thrombectomy enhances clot clearance and improves hemodynamic parameters without increasing bleeding risk, an important step toward refining pulmonary embolism management.

Monday, October 27, delves deeply into valvular heart disease and long-term device outcomes. The PREVUE-VALVE study presents critical epidemiological data defining the prevalence of valvular disease among the older American population, drawing attention to the rising clinical burden and the need for optimized screening and management pathways. Complementarily, the seven-year clinical and echocardiographic follow-up of the PARTNER 3 low-risk randomized trial provides invaluable insights into the durability and safety profile of transcatheter aortic valve replacement (TAVR) in a broader demographic.

Technological innovation in mitral valve interventions takes center stage with presentations on the Tendyne Transcatheter Mitral Valve System and the SAPIEN M3 balloon-expandable valve, both examining outcomes in complex mitral annular calcification and transseptal mitral valve replacement, respectively. These studies exemplify the ongoing evolution of structural heart disease therapy toward less invasive, catheter-based solutions with durable, physiological restoration of valve function.

Further enriching the program is the INFINITY-SWEDEHEART randomized trial, which contrasts the Bioadaptor device—a novel bioresorbable scaffold—against contemporary drug-eluting stents in coronary artery disease. In parallel, the OCVC-BIF study interrogates the comparative utility of drug-coated versus conventional balloons for side branch treatment in bifurcation lesions, a niche yet highly relevant clinical scenario prone to restenosis and procedural complexity.

Tuesday, October 28, features pivotal data addressing revascularization strategies in surgical and STEMI populations. The PROCTOR trial offers a landmark comparison of PCI in native coronary arteries versus saphenous vein grafts in post-coronary artery bypass surgery patients, shedding light on procedural success rates, graft patency, and long-term clinical endpoints. The adjunctive use of low-dose intracoronary recombinant tissue plasminogen activator during primary PCI in STEMI patients with large thrombus burdens, assessed in a randomized double-blind trial, could further advance reperfusion strategies and mitigate microvascular obstruction.

The agenda also includes innovative approaches leveraging advanced imaging and physiological assessments to guide revascularization. For instance, the comparison of instantaneous wave-free ratio (iFR) versus cardiac magnetic resonance imaging (MRI) guided strategies for treating non-culprit lesions in ST-elevation myocardial infarction patients represents a cutting-edge attempt to individualize intervention based on functional and tissue characterization markers. Moreover, the PROMISE trial’s stratified treatment approach for myocardial infarction with non-obstructive coronary arteries (MINOCA) addresses an under-recognized patient subset, highlighting the challenge of tailored therapy in heterogeneous pathophysiologies.

Device innovation rigor continues with head-to-head randomized trials such as TUXEDO-2, comparing Supraflex Cruz with Xience drug-eluting stents in diabetic patients with multivessel coronary disease. The 3-year results of the iCABG trial offer new perspectives on the role of angiography and physiology in guiding coronary artery bypass grafting. Additionally, the TALENT multicenter study pits Supraflex CruzTM stents against SYNERGYTM, pushing the frontier in scaffold technology and polymer design.

Complementing the interventional studies, a prospective trial evaluating hemodynamic support devices—novel percutaneous ventricular assist devices (pVADs) versus intra-aortic balloon pumps (IABP)—will provide insightful data on circulatory support strategies for high-risk PCI cases. Meanwhile, the AI-enabled ECG interpretation trial in STEMI patients from a multicenter U.S. registry exemplifies the transformative interface of artificial intelligence with acute cardiovascular care, promising earlier detection and swift therapeutic escalation.

Finally, the INVEST CTO single-arm study explores planned investment procedures in high-risk chronic total occlusions, an area with significant procedural complexity and risk where scaffold scaffolding or lesion preparation strategies may vastly improve success rates.

The upcoming TCT® 2025 promises an unparalleled confluence of scientific breakthroughs and clinical insights, reinforcing its standing as a preeminent forum that equips cardiovascular specialists with the latest evidence to enhance patient survival, quality of life, and procedural safety. Media engagement and open dissemination of these results will expedite their translation from bench to bedside, ultimately shaping the future landscape of cardiovascular therapeutics.

Subject of Research: Late-breaking clinical trials and innovations in interventional cardiovascular medicine presented at TCT® 2025.

Article Title: Revolutionizing Cardiovascular Care: A Preview of Late-Breaking Trials and Innovations at TCT® 2025

News Publication Date: August 27, 2025

Web References:
https://www.tctconference.com/late-breaking-research
https://www.tctconference.com/press-registration
https://x.com/crfheart
http://www.crf.org
http://www.tctconference.com

Keywords: Interventional cardiovascular medicine, percutaneous coronary intervention, drug-eluting stents, intravascular lithotripsy, pulmonary embolism, valvular heart disease, transcatheter mitral valve replacement, bioresorbable scaffolds, coronary artery bypass grafting, STEMI, myocardial infarction, drug-coated balloons, artificial intelligence in cardiology

Platelets, tiny but vital components in blood, act as first responders during vascular injury, aggregating rapidly to seal wounds and prevent excessive bleeding. However, in individuals with CAD, these platelets may go into overdrive, creating hazardous clots that block arterial blood flow, ultimately heightening the risk of heart attacks and strokes. Despite the importance of controlling platelet activity with antiplatelet drugs, doctors have long faced challenges in accurately measuring the effectiveness of these treatments on a patient-by-patient basis. This uncertainty leaves critical gaps in optimizing therapeutic interventions.

To tackle this issue, Dr. Kazutoshi Hirose and his team developed an innovative system that captures platelets in action with remarkable clarity and speed. At the heart of this innovation is an FDM microscope—a sophisticated optical device capable of taking thousands of high-resolution images of blood cells flowing through vessels every second. Unlike traditional microscopes, this technology moves beyond static imaging, effectively acting as a high-speed camera filming the dynamic interactions of cells in real-time.

Once the FDM microscope generates these rapid-fire images, the research team employs AI algorithms specifically trained to distinguish between individual blood components in motion. The AI is adept at recognizing solitary platelets, clusters of platelets, and even white blood cells, which can sometimes interact with or influence clot formation. This level of precise categorization is crucial, as the formation and size of platelet aggregates directly correlate with clotting risk and the severity of CAD symptoms.

The research, involving over 200 patients, revealed significant differences in platelet aggregation between those suffering from acute coronary syndrome and patients with more stable, chronic conditions. Acute patients exhibited markedly larger platelet clumps, a finding that aligns with heightened clotting risk and supports the technology’s potential as a predictive diagnostic tool. These insights underscore the capacity of this system to provide real-time clotting risk assessments, potentially enabling doctors to intervene more swiftly and with greater precision.

One of the most remarkable breakthroughs of the study is the discovery that simple venous blood draws from the arm deliver nearly the same valuable platelet activity information as blood sampled invasively from coronary arteries. Conventional methods require catheter insertion, a procedure that can be uncomfortable, risky, and resource-intensive. This less invasive approach promises to simplify monitoring protocols, lower patient risk, and broaden access to platelet activity testing in diverse clinical settings.

Dr. Hirose emphasized the clinical significance of these findings, highlighting that tailored therapy adjustments based on real-time platelet behavior could minimize both ischemic events caused by clots and bleeding complications associated with over-medication. This personalization aligns with the growing movement in medicine toward precision treatment, where therapies are fine-tuned according to individual patient profiles rather than a one-size-fits-all approach.

The underlying AI technology is a pivotal aspect of this research, offering capabilities far beyond human visual perception. AI’s ability to detect subtle patterns and fluctuations in platelet behavior within seconds makes it an invaluable partner in clinical diagnosis and drug efficacy evaluation. This harnessing of machine learning in biomedical imaging exemplifies the fusion of computational power and medical innovation, a trend likely to accelerate across many fields of healthcare.

Co-author Yuqi Zhou illustrated how the system mirrors traffic monitoring techniques, where a camera not only counts individual cars but also identifies traffic jams and emergency vehicles. In the bloodstream, single platelets are akin to individual cars, platelet clumps resemble traffic jams, and white blood cells are like police cars that can influence the scene. Such analogies help conceptualize the complexity and high-resolution detection capacity of the technology.

Professor Keisuke Goda, the project’s lead, reflected on the transformative potential of combining high-speed optical imaging with AI, stressing how these advances allow unprecedented observation of blood cells in their natural flowing state. This approach shatters previous limitations of static slide samples or indirect testing, opening new avenues for real-time blood analysis and cardiovascular risk assessment.

Beyond CAD, the implications for this technology could extend to other disorders involving abnormal blood clotting, including stroke, deep vein thrombosis, and certain inflammatory diseases. By providing a window into the microscopic blood traffic with fine detail and speed, this FDM microscope and AI system might redefine both diagnostics and the monitoring of therapeutic responses in various hematologic conditions.

Looking forward, the researchers aim to integrate this technology into clinical workflows, enabling more frequent and less invasive monitoring of at-risk patients. The ultimate vision is a new standard of care where personalized antiplatelet treatments are dynamically adjusted based on continuous or periodic direct observation of platelet behavior, enhancing both safety and efficacy.

This study, published in Nature Communications, underscores the power of interdisciplinary collaboration—melding optics, machine learning, and clinical medicine—to address longstanding challenges in cardiovascular health. It stands as a compelling example of how emergent technologies can reveal hidden physiological stories that ultimately improve patient outcomes and save lives.

Subject of Research: Human tissue samples
Article Title: Direct evaluation of antiplatelet therapy in coronary artery disease by comprehensive image-based profiling of circulating platelets
News Publication Date: 15-May-2025
Web References: http://dx.doi.org/10.1038/s41467-025-59664-8
References: Kazutoshi Hirose et al., Nature Communications, 2025
Image Credits: ©2025 Hirose et al CC-BY-ND
Keywords: platelet aggregation, coronary artery disease, FDM microscope, artificial intelligence, antiplatelet therapy, high-speed imaging, blood clotting, cardiovascular risk, non-invasive diagnostics, real-time monitoring